GlassScriptPhysician profile
Patrick X Landazuri
NPI 1427212836
$9,703.88
in general payments reported to CMS, 2019-2025
8 companies · $5,258 in 2025
The $5,258 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,274 · 2020: $11.95 · 2021: $142 · 2022: $45.66 · 2024: $972 · 2025: $5,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,745 · Food and Beverage: $1,158 · Travel and Lodging: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,745.00 |
| Food and Beverage | $1,158.47 |
| Travel and Lodging | $326.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $6,328.96 | 2019-2025 | |
| Monteris Medical Corporation | $2,925.66 | 2019-2024 | Neuroblate |
| Eisai INC. | $227.38 | 2019-2022 | |
| Sk Life Science, INC. | $144.20 | 2021-2025 | Xcopri |
| Supernus Pharmaceuticals, INC. | $30.25 | 2021-2022 | |
| Medtronic, INC. | $21.84 | 2025 | Percept PC Brainsense |
| Hospira, INC. | $13.64 | 2024 | |
| Aprecia Pharmaceuticals, LLC | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Landazuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.